Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




DPC Granted License to Develop Cancer Diagnostics

By HospiMedica staff writers
Posted on 28 Jan 2003
A license to develop and commercialize diagnostic assays based on two novel prostate-specific proteins for detecting and monitoring prostate cancer and perhaps other cancers has been granted to Diagnostic Products Corp. More...
(Los Angeles, CA, USA) by Compugen, Ltd. (Tel Aviv, Israel). In return, Compugen will receive milestone payments and royalties based on the commercialization of its intellectual property.

The agreement couples DPC's ability to manufacture and market immunoassay-based products with Compugen's recent discoveries of a molecule linked to prostate-specific antigen (PSA-LM) and an hK2-linked molecule (K-LM). The two proteins are encoded by alternative mRNA splice variants of the genes for PSA and a related protein, human kallikrein 2 (hK2). PSA and human kallikrein 2 are closely related products of human kallikrein genes KLK3 and KLK2, respectively. Both proteins are secreted by the prostate and play important roles as biomarkers in the diagnosis of prostate cancer.

"This alliance is another strong validation of our continuing assertion that Compugen's unique computational biology research can result in the discovery of meaningful biologic information that would otherwise be extremely difficult to discover solely through experimentation,” said Mor Amitai, Ph.D., president and CEO of Compugen.





Related Links:
DPC
Compugen

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Tourniquet System
heidi– mein Tourniquet
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.